UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

The use of in vivo thermoluminescent dosimeters in the quality assurance programme for the START breast fractionation trial

Venables, K; Miles, EA; Aird, EGA; Hoskin, PJ; (2004) The use of in vivo thermoluminescent dosimeters in the quality assurance programme for the START breast fractionation trial. Radiotherapy and Oncology , 71 (3) pp. 303-310.

Full text not available from this repository.

Abstract

Background and purpose: The use of in vivo dosimetry for patient measurement is recommended in many publications. It provides an additional check to verify that the dose delivered to the patient corresponds to the prescribed dose. In the context of a clinical trial investigating the effects of different fractionation regimens, it is imperative that the dose given is that prescribed to ensure that noise in the data between centres does not mask the results of the trial. The methodology for in vivo measurement in a clinical trial of breast radiotherapy was developed and verified. Materials and methods: A cohort of patients in the STAndardisation of breast RadioTherapy (START) trial was monitored using postal thermoluminescent dosimeters chips (TLD). All TLD were processed and analysed at Mount Vernon Hospital. Patients for in vivo measurements were identified at randomisation as a random 1 in 9 samples for the first 2500 patients randomised (282 TLD) increasing to 1 in 3 thereafter. The TLD were left in place for the duration of the tangential field treatment and thus a composite entrance and exit dose was recorded. Results: TLD measurements were performed on 429 patients from 33 hospitals. The average ratio of dose measured using TLD to that prescribed was 0.99 +/- 0.04. Eight patients had initial measurements more than 10% different to the prescribed dose. The mean TLD results for a given centre correlated well with dose measurements performed using an ionisation chamber in a breast shaped phantom at that centre as part of the START trial audit. Conclusion: Thermoluminescence dosimetry has provided useful quality assurance information on the doses received by patients in centres participating in the START trial. (C) 2004 Elsevier Ireland Ltd. All rights reserved

Type: Article
Title: The use of in vivo thermoluminescent dosimeters in the quality assurance programme for the START breast fractionation trial
Additional information: WoS ID: 000222219200009 JournalEnglishArticle27ELSEVIER SCI IRELAND LTD*ICRU, 1976, 24 ICRU; *ICRU, 1993, 50 ICRU; *START TRIAL MAN G, 1999, CLIN ONCOL, V11, P145; ADEYEMI A, 1997, BRIT J RADIOL, V70, P399; BRIDIER A, 2000, RADIOTHER ONCOL, V55, P285; DAVIS JB, 1999, RADIOTHER ONCOL, V52, P65; DELANCY G, 2000, RADIOTHER ONCOL, V57, P61; DUCH MA, 1998, RADIOTHER ONCOL, V47, P319; DUTREIX A, 1994, RADIOTHER ONCOL, V32, P256; DUTREIX A, 1993, RADIOTHER ONCOL, V29, P97; ESSERS M, 1996, VIVO DOSIMETRY RADIO; HAMERS HP, 1991, RADIOTHER ONCOL, V22, P280; HARRIS CK, 1997, MED PHYS, V24, P1527; HEUKELOM S, 1991, RADIOTHER ONCOL, V22, P269; IZEWSKA J, 1995, ACTA ONCOL, V34, P829; KIRBY TH, 1992, MED PHYS, V19, P1427; KNOOS T, 1986, RADIOTHER ONCOL, V7, P81; LEUNENS G, 1991, RADIOTHER ONCOL, V22, P285; LONCOL T, 1996, RADIOTHER ONCOL, V41, P179; MIJNHEER BJ, 1987, RADIOTHER ONCOL, V8, P237; NOEL A, 1995, RADIOTHER ONCOL, V34, P144; RIZZOTTI A, 1985, RADIOTHER ONCOL, V3, P279; SWINNEN A, 2002, RADIOTHER ONCOL, V64, P317; VENABLES K, 2003, INT J RADIAT ONCOL, V55, P271; VENABLES K, 2001, PHYS MED BIOL, V46, P1937; WINFIELD E, 2002, CLIN ONCOL-UK, V14, P267; WOOD JJ, 1995, PHYS MED BIOL, V40, P3090JUN831TOCLAREVenables K Mt Vernon Hosp, Marie Curie Res Wing, Rickmansworth Rd, Northwood HA6 2RN, Middx, EnglandRADIOTHER ONCOLCUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND
Keywords: AUDIT, BREAST, breast radiotherapy, CALIBRATION, DOSE MEASUREMENTS, ENTRANCE, EUROPE, in vivo measurement, IN-VIVO, INVIVO DOSIMETRY, IRRADIATION, PHANTOM, PHOTON BEAMS, radiotherapy, RADIOTHERAPY CENTERS, thermoluminescent dosimeters chips, TRIAL, trials quality assurance
UCL classification: UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
URI: http://discovery.ucl.ac.uk/id/eprint/36748
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item